<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45205">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01878526</url>
  </required_header>
  <id_info>
    <org_study_id>GERD therapy in scleroderma</org_study_id>
    <secondary_id>PPI in SSc-GERD</secondary_id>
    <nct_id>NCT01878526</nct_id>
  </id_info>
  <brief_title>Gastroesophageal Reflux Treatment in Scleroderma</brief_title>
  <acronym>GERD-SSc</acronym>
  <official_title>The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <authority>Thailand: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators purposes are to define the prevalence of omeprazole resistance
      gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy
      of omeprazole in combination with algycon versus omeprazole in combination with domperidone
      on the severity of reflux symptoms in omeprazole resistant GERD in SSc, and to compare the
      efficacy of omeprazole in combination with algycon versus omeprazole in combination with
      domperidone on the frequency of symptoms in omeprazole- resistant GERD in SSc.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changing severity of heart burn and regurgitation of SSc related omeprazole resistant GERD evaluated by visual analogue score (VAS)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>changing of frequency of symptoms in SSc related omeprazole resistant GERD evaluated by frequency scale for the symptoms of GERD (FSSG) and the quality of life which is evaluated by EQ-5DTM (by EuroQol Group)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the prevalence of omeprazole-resistant GERD in SSc after 4 weeks treatment with omeprazole</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>Systemic Sclerosis</condition>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>Omeprazole plus alginic acid and placebo of domperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole plus domperidone and placebo of alginic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alginic acid</intervention_name>
    <description>Algycon 1 tab chew tid after meal</description>
    <arm_group_label>Omeprazole plus alginic acid and placebo of domperidone</arm_group_label>
    <other_name>Algycon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (for domperidone)</intervention_name>
    <description>placebo (for domperidone) 1 tab oral tid before meal</description>
    <arm_group_label>Omeprazole plus alginic acid and placebo of domperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>domperidone (10 mg) 1 tab oral tid before meal</description>
    <arm_group_label>Omeprazole plus domperidone and placebo of alginic acid</arm_group_label>
    <other_name>Molax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (of alginic acid)</intervention_name>
    <description>placebo (for alginic acid) 1 tab chew tid after meal</description>
    <arm_group_label>Omeprazole plus domperidone and placebo of alginic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 1 SSc patients who fit all inclusion and exclusion criteria will be eligible to
        phase 1 study for evaluation the prevalence of omeprazole resistant-GERD

        Inclusion criteria:

          1. SSc patients aged between 18 and 65 years.

          2. Clinically diagnosed as GERD and GERD-questionnaire score &gt;3

          3. Must not receive any proton pump inhibitor (PPI) or prokinetic drug within 2 weeks
             before baseline evaluation

        Exclusion criteria:

          1. Pregnancy or lactation

          2. Previous history of gastroesophageal surgery or endoscopic therapy due to severe
             erosive esophagitis

          3. Present of Barrett's esophagus

          4. Bedridden and confined to no self-care

          5. Evidence of active malignant disease

          6. Present of uncontrolled or severe medical problems such as asthma, angina, hepatic or
             renal diseases

          7. Present of active infection that needs systemic antibiotic

          8. Allergic history of omeprazole

          9. Receiving prohibit co-medications that may have drug interaction or attenuate GERD
             symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate

        Phase 2 randomized parallel study SSc patients who fit all inclusion and exclusion
        criteria will be eligible to phase 2 study.

        Inclusion criteria:

          1. SSc patients who completed the phase 1 study.

          2. The subjects were defined as PPI-resistance.

          3. The subject must be willing to continue phase 2 study.

        Exclusion criteria:

          1. Pregnancy

          2. Present of uncontrolled or severe medical problems

          3. Present of active infection

          4. Allergic history of alginic acid or domperidone

          5. Receiving prohibit co-medications that may have drug interaction or attenuate GERD
             symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate

          6. Chewing difficulty
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chingching Foocharoen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chingching Foocharoen, MD</last_name>
    <phone>6643363746</phone>
    <email>fching@kku.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>123 Department of Medicine, Faculty of Medicine, Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chingching Foocharoen, MD</last_name>
      <phone>6643363746</phone>
      <email>fching@kku.ac.th</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 24, 2013</lastchanged_date>
  <firstreceived_date>June 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Chingching Foocharoen</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>gastroesophageal reflux disease</keyword>
  <keyword>heart burn</keyword>
  <keyword>regurgitation</keyword>
  <keyword>systemic sclerosis</keyword>
  <keyword>scleroderma</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>alginic acid</keyword>
  <keyword>omeprazole</keyword>
  <keyword>prokinetic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Domperidone</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Alginic acid</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
